PEG5-bis-(Ethyl phosphonate)

 CAS No.: 1446282-28-5  Cat No.: BP-501175 4.5  

PEG5-bis-(Ethyl phosphonate) is a polyethylene glycol–based bifunctional linker bearing two ethyl phosphonate groups at the termini of a five–ethylene glycol chain. The diethyl phosphonate termini are neutral, protected phosphonate groups that can be de-esterified to phosphonic acids when needed, while the PEG segment imparts aqueous solubility and conformational flexibility. In PROTAC and targeted degradation workflows, such a linker can be used to spatially separate and tune the relative orientation of the two cooperating ligands (a target-binding moiety and an E3 ligase recruiter), thereby influencing productive ternary complex formation and degradation efficiency. Its PEG backbone can reduce nonspecific hydrophobic interactions and improve handling in biological buffers, while the bis-phosphonate ends mainly serve as protected polar motifs rather than standard direct covalent-coupling handles. This makes PEG5-bis-(Ethyl phosphonate) a useful scaffold for systematic linker optimization in targeted protein degradation research.

PEG5-bis-(Ethyl phosphonate)

Structure of 1446282-28-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
PROTAC Linker
Molecular Formula
C₂₀H₄₄O₁₁P₂
Molecular Weight
522.50

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping
Room temperature in continental US; may vary elsewhere.
IUPACName
1-[2-(2-diethoxyphosphorylethoxy)ethoxy]-2-[2-[2-(2-diethoxyphosphorylethoxy)ethoxy]ethoxy]ethane
InChI Key
GAJCGHAUFHRSDD-UHFFFAOYSA-N
InChI
InChI=1S/C20H44O11P2/c1-5-28-32(21,29-6-2)19-17-26-15-13-24-11-9-23-10-12-25-14-16-27-18-20-33(22,30-7-3)31-8-4/h5-20H2,1-4H3
SMILES
CCOP(=O)(CCOCCOCCOCCOCCOCCP(=O)(OCC)OCC)OCC
1. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas
K U Schallreuter, J M Wood Melanoma Res. 1991 Aug-Sep;1(3):159-67.
The importance of thioproteins, essential to the ribonucleotide reduction pathway, has been demonstrated in human primary and metastatic melanoma tissues. The thioredoxin reductase/thioredoxin and the glutathione reductase/glutathione/glutaredoxin electron transfer pathways represent alternative electron donors for ribonucleotide reductase and regulate the synthesis of deoxyribonucleotides, the substrates for DNA synthesis, in the S phase of the cell cycle. In addition to their important role in DNA synthesis and cell division, these thioproteins provide effective antioxidant defence against oxygen radicals and hydrogen peroxide. In human metastatic melanoma cells and tissues the thioredoxin reductase/thioredoxin system is located both in the cell cytosol and on plasma membranes and is under allosteric regulation by calcium. As a consequence, calcium plays an important role in determining the intracellular redox status, cell division and differentiation. Recently, the intracellular redox conditions have been shown to be important in the reaction of alkylating anti-tumour drugs such as the chloroethylnitrosoureas. In addition to previously established mechanisms, these highly reactive drugs inhibit thioredoxin reductase, glutathione reductase and ribonucleotide reductase by chloroethylation of their respective thiolate active sites. Incorporation of the 14C chloroethyl group in drug sensitive and resistant human metastatic melanoma cell lines depends on the redox status, with resistant cells being more oxic than sensitive cells. Thioredoxin reductase is 500-fold more sensitive than glutathione reductase to the newly developed nitrosourea, Fotemustine (diethyl-1-[3,2 chloroethyl]-3-nitrosoureido ethyl phosphonate). It has been shown that melanomas which respond to Fotemustine therapy contain more thioredoxin reductase whereas resistant metastases yielded the opposite result.(ABSTRACT TRUNCATED AT 250 WORDS)
2. Enhanced Osteogenic Potential of Phosphonated-Siloxane Hydrogel Scaffolds
Michael T Frassica, Sarah K Jones, Jakkrit Suriboot, Ahmad S Arabiyat, Esteban M Ramirez, Robert A Culibrk, Mariah S Hahn, Melissa A Grunlan Biomacromolecules. 2020 Dec 14;21(12):5189-5199.doi: 10.1021/acs.biomac.0c01293.Epub 2020 Nov 2.
In a material-guided approach, instructive scaffolds that leverage potent chemistries may efficiently promote bone regeneration. A siloxane macromer has been previously shown to impart osteoinductivity and bioactivity when included in poly(ethylene glycol) diacrylate (PEG-DA) hydrogel scaffolds. Herein, phosphonated-siloxane macromers were evaluated for enhancing the osteogenic potential of siloxane-containing PEG-DA scaffolds. Two macromers were prepared with different phosphonate pendant group concentrations, poly(diethyl(2-(propylthio)ethyl)phosphonate methylsiloxane) diacrylate (PPMS-DA) and 25%-phosphonated analogue (PPMS-DA 25%). Macroporous, templated scaffolds were prepared by cross-linking these macromers with PEG-DA at varying mol % (15:85, 30:70, and 45:55 PPMS-DA to PEG-DA; 30:70 PPMS-DA 25% to PEG-DA). Other scaffolds were also prepared by combining PEG-DA with PDMS-MA (i.e., no phosphonate) or with vinyl phosphonate (i.e., no siloxane). Scaffold material properties were thoroughly assessed, including pore morphology, hydrophobicity, swelling, modulus, and bioactivity. Scaffolds were cultured with human bone marrow-derived mesenchymal stem cells (normal media) and calcium deposition and protein expression were assessed at 14 and 28 days.
3. Supramolecular architecture in azaheterocyclic phosphonates. III. Structures of an ethyl phosphonamidate and an ethyl phosphonate
Anna Pietrzak, Jakub Modranka, Jakub Wojciechowski, Tomasz Janecki, Wojciech M Wolf Acta Crystallogr C Struct Chem. 2018 Aug 1;74(Pt 8):907-916.doi: 10.1107/S2053229618009609.Epub 2018 Jul 13.
The novel crystal structures of ethyl (S)-P-(4-oxo-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-3-yl)-N-[(R)-1-phenylethyl]phosphonamidate, C20H20N3O3PS, I, and diethyl (4-isopropyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidin-3-yl)phosphonate, C18H25N2O4PS, II, were characterized by X-ray diffraction analysis. The crystal packing of I is dominated by two infinite stacks composed of symmetry-independent molecules linked by distinctively different hydrogen-bond systems. The structure of II shows a ladder packing topology similar to those observed in related phosphorylated azaheterocycles. Structural studies are supplemented by calculations on the interactions stabilizing the molecular assemblies using the PIXEL method. Additionally, fingerprint plots derived from the Hirshfeld surfaces were generated for each structure to characterize the crystal packing arrangements in detail. The aromaticities of the heterocyclic moieties have been investigated using HOMA and HOMHED parametrization and compared with structures reported previously.

PEG5-bis-(Ethyl phosphonate) is a bifunctional, PEG-based linker designed to support targeted protein degradation workflows by enabling robust conjugation between PROTAC-binding modules. Its phosphonate termini provide chemically addressable handles that can be used to assemble linker architectures with controlled spacing and improved solubility. The resulting constructs are well suited for building PROTACs where stable, water-compatible linkers are advantageous; detailed structural and reactivity considerations are provided below.

Structure: The linker consists of an ethylene glycol (PEG) scaffold bearing two ethyl phosphonate groups at the termini. It features ether linkages within the PEG chain and fully esterified diethyl phosphonate termini; no phosphonic-acid P–OH groups are present in the protected form. Overall, it is expected to be flexible and hydrophilic, supporting aqueous handling.

Reactivity: The diethyl phosphonate groups can be converted to phosphonic acids by appropriate dealkylation if phosphonic-acid functionality is required for subsequent coupling. Direct base-mediated deprotonation of a phosphonic-acid P–OH is not applicable to these fully esterified termini; reaction planning should account for the protected diethyl phosphonate state. Solvent systems that maintain phosphonate stability and solubility of PEG conjugates are generally preferred, with reaction monitoring by standard analytical methods to confirm completion and minimize side reactions.

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code
Inquiry Basket